Croydon Health Services NHS Trust (Working in Partnership) Shared Care Guideline: Prescribing Agreement
|
|
- Penelope Parsons
- 5 years ago
- Views:
Transcription
1 Shared Care Guideline: Prescribing Agreement Section A: To be completed by the hospital consultant initiating the treatment GP Practice Details: Name: Address: Tel no: Fax no: NHS.net Consultant name: Clinic name:. Contact details: Patient Details: Name: Address: DOB: / / Hospital number: NHS number (10 digits): Address:... Tel no: Fax no: NHS.net Diagnosis: Drug name & dose to be prescribed by GP:. Next hospital appointment: / /.. Dear Dr..., Your patient was seen on../.. / and I have started.(insert drug name and dose) for the above diagnosis. I am requesting your agreement to sharing the care of this patient from../../.. in accordance with the (attached) Shared Care Prescribing Guideline (approval date:././..). Please take particular note of Section 2 where the areas of responsibilities for the consultant, GP and patient for this shared care arrangement are detailed. Patient information has been given outlining potential aims and side effects of this treatment and * supplied (* insert any support materials issued such as patient held monitoring book etc where applicable). The patient has given me consent to treatment possibly under a shared care prescribing agreement (with your agreement) and has agreed to comply with instructions and follow up requirements. The following investigations have been performed on / / and are acceptable for shared care. Please monitor...every.. Test Result Test Result. Other relevant information:.... Section B: To be completed by the GP and returned to the hospital consultant as detailed in Section A above Please sign and return your agreement to shared care within 14 days of receiving this request Tick which applies: I accept sharing care as per shared care prescribing guideline and above instructions I would like further information. Please contact me on:. I am not willing to undertake shared care for this patient for the following reason:. GP name:.. GP signature: Date: / /..
2 Shared Care Guidelines for the prescribing and monitoring of Azathioprine and 6- Mercaptopurine in adults for inflammatory bowel disease (unlicensed) and Azathioprine for Rheumatoid Arthritis (licensed) NOTES to the GP The expectation is that these guidelines should provide sufficient information to enable GPs to be confident to take clinical and legal responsibility for prescribing this drug. The questions below will help you confirm this: Is the patient s condition predictable or stable? Do you have the relevant knowledge, skills and access to equipment to allow you to monitor treatment as indicated in this shared care prescribing guideline? Have you been provided with relevant clinical details including monitoring data? If you can answer YES to all these questions (after reading this shared care guideline), then it is appropriate for you to accept prescribing responsibility. If the answer is NO to any of these questions, you should not accept prescribing responsibility. You should write to the consultant within 14 days, outlining your reasons for NOT prescribing. If you do not have the confidence to prescribe, we suggest you discuss this with your local Trust/specialist service, which will be willing to provide training and support. If you still lack the confidence to accept clinical responsibility, you still have the right to decline. Your PCT pharmacist will assist you in making decisions about shared care. It would not normally be expected that a GP would decline to share prescribing on the basis of cost. The patient s best interests are always paramount Date Prepared: August 2012 Approved on behalf of Croydon CCG by; Croydon Prescribing committee Date approved; 4 th January 2013 Review date; January 2015 Prepared by; Helen McGowan, Senior Pharmacist, CHS Dr Mendall, Consultant Gastroenterologist This box should be used to confirm that shared care has been agreed between the consultant and GP. And faxed to the choice support team on fax number Patient Name; Drug Name; Patient ID / DOB; Indication; Consultant Name; Consultant Signature; GP Name; GP Signature;
3 1. CIRCUMSTANCES WHERE SHARED CARE IS APPROPRIATE; Prescribing responsibility will only be transferred when the consultant and the GP are in agreement that the patient s condition is stable or predictable. Patients will only be referred to the GP once the GP has agreed in each individual case and the hospital will continue to provide prescriptions and blood monitoring until successful transfer of responsibilities as outlined below. The hospital will provide the patient with a minimum initial supply of 8 weeks therapy. 2. AREAS OF RESPONSIBILITY Consultant Pre-treatment checks:- Consider possible drug interactions with current medication. Conduct baseline tests; FBC, LFTs, U&Es, TPMT. Patient education:- Discuss benefits vs risks with the patient and explain the need for long term monitoring. Provide adequate verbal and written information for patients and relatives on the disease, treatment and side effects obtain written consent. Include contact number if patient experiences adverse effects or feels unwell. Issue / explain Patient held medicines monitoring record booklet. Record baseline blood tests in the booklet. Educate patient on the increased risk of bleeding and what action to take. Discuss pregnancy with the patient and advise on contraception. Inform and document that patient is aware of unlicensed indication. Starting of treatment:- Issue hospital prescriptions until patient is stabilised and shared care agreed, (Prescriptions to be issued in 4 week amounts with a minimum of 8 weeks.) Communicate test results to GP Subsequently:- Provide monitoring until the GP has agreed to participate in shared care. Report adverse events to the CSM and GP. Shared care:- Send completed shared care protocol to GP and ask GP to continue prescribing and monitor blood results. Inform GP of baseline test results and next review date Advise the GP of any dosage adjustments required, when to refer back and when and how to stop treatment. The specialist will assess and monitor the patient s response to treatment. GP Shared Care Notify hospital within 14 days, once GP has been asked to take on prescribing, if not willing to prescribe Azathioprine / 6-Mercaptopurine under shared care. Save copy of signed shared care guideline in patient s records. Return/fax back GP signed copy of shared care to hospital and choice team for record. Continue to prescribe and monitor Azathioprine / 6-Mercaptopurine in line with hospital recommendation, (see page 4 monitoring requirements.) Record indication, dosing information, monitoring requirements, blood tests on practice computer system. Extract relevant information from letters if necessary. Record blood tests in the Patient held Medicines Monitoring record booklet and practice computer system. Check patient dose record book prior to issuing each prescription Inform patient of monitoring schedule and repeat prescribing arrangements Refer to guidelines if results are not within the normal range, or if there is an adverse effect and take the appropriate action given. Monitor for drug interactions see under clinical information. Adjust dose/ stop treatment as advised by specialist. Monitor the patient s overall health status. Report adverse events to the specialist and CSM. Ensure patients on Azathioprine / 6- Mercaptopurine are given priority GP appointments if they have symptoms of sore throat/sore mouth, cough, breathlessness, bruising, bleeding etc. Ensure practice staff are aware of this.
4 3. CLINICAL INFORMATION Indication 1. Treatment of inflammatory bowel disease, including ulcerative colitis and crohn s disease. (Unlicensed indication CPC has approved the use of these drugs for these unlicensed indication) 2. Treatment of rheumatoid arthritis. Place in Therapy As above Therapeutic summary 6-Mercaptopurine is a metabolite of Azathioprine. It is an antimetabolite agent. Its precise mechanism of action is unknown. Dose and route of Azathioprine (for inflammatory bowel disease): administration PO route; Adult over 18 years, 2-2.5mg/kg daily. Azathioprine (for rheumatoid arthritis): PO route; Adult over 18 years,1-3mg/kg daily Summary of adverse effects (See summary of product characteristics (SPC) for full list) Very common: 1/10 Common: 1/100 and <1/10 Uncommon: 1/1000 and <1/100 : >1/10,000 and <1/1000 Very rare: <1/10,000 Monitoring requirements 6-Mercaptopurine (for inflammatory bowel disease only:) PO route; Adult over 18 years, 1-1.5mg/kg daily. Adverse Effect Frequency Depression of bone marrow function; leucopenia Very Common Thrombocytopenia Common Anaemia Uncommon Agranulocytosis, pancytopenia, aplastic anaemia, megaloblastic anaemia, erythriod hypoplasia Pancreatitis Severe diarrhoea in IBD population Cholestasis and degeneration of liver functions Uncommon Viral, fungal and bacterial infections Uncommon Reversible pneumonitis Very rare Alopecia, photosensitivity Hypersensitivity reaction Uncommon Steven s Johnson s syndrome and toxic Very rare epidermal necrolysis. Baseline tests will be performed by the specialist and prescriptions will be issued at 4 week intervals until patient is stabilised and GP agrees shared care. Prescribing and monitoring responsibilities are retained by the hospital until shared care is accepted. Monitoring to be performed by GP once shared care accepted. Monitoring requirements; Test FBC & LFTs Urea, Creatinine and egfr TPMT Varicella statue Frequency At initiation, twice weekly for 8 weeks, then monthly for 4 months, then 3 monthly if stable. At initiation then 3 monthly At initiation At initiation
5 Summary of Management of Adverse Effects Clinically relevant drug interactions Croydon Health Services NHS Trust Blood Test Results Lymphocytes <0.5 x 10 9 /L Neutrophils < 2.0 x 10 9 /L < 1.5 x 10 9 /L Platelets Action Discuss with specialist hospital nurse / clinician. Discuss with specialist hospital nurse / clinician Stop and discuss with specialist hospital nurse / clinician < 150 x 10 9 /L Discuss with specialist hospital nurse / clinician Liver function tests >2 fold rise in AST, ALT Discuss with specialist hospital nurse / clinician (from upper limit of reference range) > 4 fold rise in AST, ALT Stop 6-mercaptopurine / Azathioprine and discuss with specialist hospital nurse / clinician immediately. Symptoms Action Rash (significant new) Stop 6-mercaptopurine / Azathioprine and check FBC. If FBC abnormal contact specialist nurse or clinician. Wait until rash resolved and consider restarting at reduced dose, providing no blood dyscrasias. Severe or persistent Stop 6-mercaptopurine /Azathioprine, check FBC infections, fever, chills. and contact specialist nurse or clinician. Do not Persistent sore throat restart until results of FBC known. For sore throat throats, take FBC and discuss with Abnormal bruising or bleeding Varicella Nausea hospital specialist. Stop 6-mercaptopurine/ Azathioprine until recovery and check FBC. Do not restart if blood test abnormal, contact specialist nurse or clinician. If in contact with the virus, contact hospital specialist nurse or clinician. Advise patient to divide dosage and take with food. If no improvement, reduce dosage or stop and contact specialist nurse or clinician if reducing dose is ineffective Allopurinol; Enhanced effect and increased toxicity of Azathioprine /6- Mercaptopurine when given with Allopurinol (Reduce the dose of Azathioprine / 6- Mercaptopurine to one quarter of usual dose.) Coumarins including Warfarin; Azathioprine / 6-Mercaptopurine possibly reduces the anticoagulant effect. Ribavirin; Myelosuppressive effects of Azathioprine possibly enhanced. Febuxostat; Avoidance of Azathioprine / 6-Mercaptopurine advised by the manufacturer. Co-trimoxazole / Trimethoprim; Increased risk of haematological toxicity when given together with Azathioprine /6-Mercaptopurine. This has been seen in transplant patients. Other evidence suggests the drugs may be used safely together and the combination is used frequently in practice. Infliximab; May increase levels of Azathioprine / 6-Mercaptopurine.
6 References Summary of Product Characteristics Imuran Tablets 25mg. CODYNAMIC_PROPS Accessed on 30/7/12. British National Formulary 63. March Stockleys Drug Interactions. Accessed via on 30/7/12. NPSA RRR001 Risks of incorrect dosing of anticancer medicines 22/1/08. Accessed via on 24/10/ COMMUNICATION AND SUPPORT Hospital contacts (the referral letter will indicate named consultant): Croydon University Hospital Tel: Gastroenterology Dr Mike Mendall; via 3101 Dr Sanjay Gupta; via 3101 IBD Nurse;4484 Rheumatology Dr Natalie Horwood; via 3010 Dr Sarah Levy; via 3010 Dr Rosh Sathanathan; via 3010 Pharmacy Medicines information:3059 Out of hours contacts and procedure; Medical Registrar on call
Azathioprine. Shared Care Agreement for the treatment of Ulcerative colitis and Crohn s disease with Azathioprine, March 2012 Page 1 of 6
Azathioprine Shared Care Agreement for the treatment of Ulcerative colitis and Crohn s disease with azathioprine, a copy of which must be supplied by the specialist to the GP at commencement, which will
More informationSHARED CARE GUIDELINE: Unlicensed use of Mercaptopurine for the treatment of Inflammatory Bowel Disease.
LINCOLNSHIRE CLINICAL COMMISSIONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: Unlicensed use of Mercaptopurine for the treatment of Inflammatory Bowel Disease.
More informationLINCOLNSHIRE CLINICAL COMMISSIONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST
LINCOLNSHIRE CLINICAL COMMISSIONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: Azathioprine covering use in Dermatology and Gastroenterology All prescribing of
More informationMartina Khundakar - Senior Clinical Pharmacist Teresa Barnes - Lead Clinical Pharmacist - Specialist Care. Timothy Donaldson, Trust Chief Pharmacist
Policy on Pharmacological Therapies Practice Guidance Note The use of Oral Anti-Cancer Medicines and Oral Methotrexate within - V03 V03 - Issued Issue 1 Dec 15 Planned review December 2018 PPT-PGN 09 Part
More informationBSG guidelines for the management of IBD. Review Date: 1/6/2015. Issue Status: Approved Issue No: 1 Issue Date: June 2013
Title: Authors Name: Cath Stansfield Contact Name: Cath Stansfield Contact Phone No: 2064023 Authors Division: Salford Health Care Departments/Groups This Document Applies to: Gastroenterology Scope: Trust
More informationConsultation Group: See relevant page in the PGD. Review Date: October 2015
Patient Group Direction For The Supply Of Trimethoprim For The Treatment Of Women With Uncomplicated Urinary Tract Infections By Nurses And Pharmacists Working Within NHS Grampian Community Pharmacies
More informationJob Title Name Signature Date
Supply of Fluconazole 150mg capsule by Community Pharmacists working in Forth Valley Pharmacies under NHS Minor Ailment Service. Protocol Number 125 Version 5 Date protocol prepared: November 2014 Date
More informationPROPOSAL TO UPDATE NEAR PATIENT TESTING ENHANCED SERVICE
PROPOSAL TO UPDATE NEAR PATIENT TESTING ENHANCED SERVICE 1.0 ACTION BY AWMSG: The All Wales Medicines Strategy Group (AWMSG) meeting held on 15 th December 2010 considered and approved the recommendations
More informationCyclophosphamide INFUSION Infusion 4 Plus
Cyclophosphamide Infusion Day DEPARTMENT OF RHEUMATOLOGY DAY CASE ADMISSION RECORD PATIENT DAY CASE BOOKING REQUEST To be completed by Consultant, Registrar requesting day case Admission Hospital No. Forename
More informationPlease call the Pharmacy Medicines Unit on or for a copy.
Title: PATIENT GROUP DIRECTION FOR THE SUPPLY OF FLUCONAZOLE 150MG UNDER THE MINOR AILMENT SERVICE Identifier: Across NHS Boards Organisation Wide Directorate Clinical Service Sub Department Area This
More informationPatient Group Direction for ACICLOVIR (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationExpiry Date: January 2009 Template Version: Page 1 of 7
YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria: Cautions/Need for
More informationPrinciples of Shared Care Protocols
Principles of Shared Care Protocols 1 Robust shared care arrangements facilitate the safe transition of medicines for use in a specified condition between secondary and primary care clinicians with the
More informationName Job Title Signed Date. This Patient Group Direction is operational from: Oct 2017 Review date: Aug 19. Expires on 31 st October 2019
PGD4017 PATIENT GROUP DIRECTION FOR THE SUPPLY OF ACICLOVIR TABLETS FOR THE TREATMENT OF GENITAL HERPES SIMPLEX INFECTIONS by registered nurses and midwives in Integrated Sexual Health services employed
More informationNHS Fife. Patient Group Direction for Named Community Pharmacists to Supply
Patient Group Direction for Named Community Pharmacists to Supply Senna tablets 7.5mg or Senna syrup 7.5mg/5ml (Total sennosides calculated as sennoside B) For patients aged 16 years and older prescribed
More informationPATIENT GROUP DIRECTION (PGD) FOR Metronidazole 400mg Tablets
Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This
More informationPATIENT GROUP DIRECTION (PGD) FOR
Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This
More informationPATIENT GROUP DIRECTION. Hepatitis A + B Vaccine (Twinrix, Twinrix paediatric, Ambirix )
PATIENT GROUP DIRECTION Administration of: By: Practice Nurses Hepatitis A + B Vaccine (Twinrix, Twinrix paediatric, Ambirix ) In: General Practice It is the responsibility of the professional working
More informationImproving compliance with oral methotrexate guidelines. Action for the NHS
Patient safety alert 13 Alert Immediate action Action Update Information request Ref: NPSA/2006/13 Improving compliance with oral methotrexate guidelines Oral methotrexate is a safe and effective medication
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cetuximab (+/- platinum-based chemotherapy) HOSPITAL NAME/STAMP: PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH:
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cetuximab (+/- Chemotherapy) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)
More informationInfliximab Infusion for Patients with Ulcerative Colitis Patient Information Leaflet
Infliximab Infusion for Patients with Ulcerative Colitis Patient Information Leaflet Originator: Lindsey Wood Date: March 2011 Version: 2 Date for Review: March 2014 DGOH Ref No: DGOH/PIL/00304 Contact
More informationNational Emergency Medicine Programme. Protocol for the administration of Paracetamol (Acetaminophen) at Triage in the Emergency Department
National Emergency Medicine Programme Protocol for the administration of Paracetamol (Acetaminophen) at Triage in the Emergency Date: November 2016 Table of Contents 1.0 Critical Elements... 3 2.0 Clinical
More informationExpiry Date: January 2009 Template Version: Page 1 of 7
YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Patients who require an antihistamine
More informationCommunity DVT Service. Phase 3: Anticoagulation at DVT Treatment Centres
Community DVT Service Quick Reference Guide Phase - Anticoagulation Phase : Anticoagulation at DVT Treatment Centres If a Patient has had a positive Ultrasound Scan they attend one of the DVT Treatment
More informationMedical Directive. July 1, 2011 Review due by: December 1, Medical Director: Date Revised: December 1, 2017
Medical Directive Assessment and Treatment of Pharyngitis in Adults (>15 yo) Assigned Number: 013 Activation Date: July 1, 2011 Review due by: December 1, 2019 Approval Signature & Date Medical Director:
More informationIBUPROFEN PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline
IBUPROFEN PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical staff in the Child Health Department and its
More informationName Job Title Signed Date
PGD3517 PATIENT GROUP DIRECTION FOR THE SUPPLY OF AZITHROMYCIN TABS/CAPS 250mg or TABS 500mg OR SUSPENSION 600mg/15mL FOR UNCOMPLICATED GENITAL CHLAMYDIA TRACHOMATIS, UNCOMPLICATED NEISSERIA GONORRHOEA
More informationSTANDING ORDERS FOR THE MANAGEMENT OF WARFARIN Dose adjustment and INR testing frequency Applicable to: Pharmacists. Issued by: Contact:
STANDING ORDERS FOR THE MANAGEMENT OF WARFARIN Dose adjustment and INR testing frequency Applicable to: Pharmacists Standing Order used for the Community Pharmacy Anticoagulant Management (CPAM) Service
More informationShared Care Agreements for Medicines
Shared Care Agreements for Medicines Author: Scott Garden, Chief Pharmacist, Acute Services Version: 1.0 Authorised by: NHS Fife Area Drug and Therapeutics Committee Date of Authorisation: Review Date:
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Gemcitabine-Doxorubicin PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
More informationPharmacy Medicine Use Review What s it all about?
Pharmacy Medicine Use Review What s it all about? 1. What is it? 1.1 Medicine use Review has been introduced under the Advanced Services tier of the New Pharmacy Contract in England & Wales. The aim of
More informationNewfoundland and Labrador Pharmacy Board
Newfoundland and Labrador Pharmacy Board Standards of Practice Prescribing by Pharmacists August 2015 Table of Contents 1) Introduction... 1 2) Requirements... 1 3) Limitations... 1 4) Operational Standards...
More informationInfliximab Infusion for Patients with Crohns Disease Patient Information Leaflet
Infliximab Infusion for Patients with Crohns Disease Patient Information Leaflet Originator: Lindsey Wood Date: March 2011 Version: 2 Date for Review: March 2014 DGOH Ref No: DGOH/PIL/00303 2 Contact Numbers
More informationPatient Group Direction for the supply of Fusidic Acid Cream 2% to patients aged over 2 years old receiving treatment from NHS Borders.
Patient Group Direction for the supply of Fusidic Acid Cream 2% to patients aged over 2 years old receiving treatment from NHS Borders. This document authorises the supply of Fusidic Acid Cream 2% by registered
More informationNPSA Alert 03: Reducing the harm caused by oral Methotrexate. Implementation Progress Report July Learning and Sharing
NPSA Alert 03: Reducing the harm caused by oral Methotrexate Implementation Progress Report July 2006 Learning and Sharing CONTENTS Page 1 Background 3 2 Findings 4 Appendix 1 Summary of responses 6 Appendix
More informationGROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE MOUTH ULCERS. Version 4 December 2017
GROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE MOUTH ULCERS Version 4 December 2017 RATIFYING COMMITTEE Drugs and Therapeutics Group DATE RATIFIED MAUP EXPIRES December 2020 EXECUTIVE SPONSOR Chief Nurse
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Gemcitabine-Cisplatin PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
More informationPATIENT GROUP DIRECTION (PGD) FOR Amoxicillin 250mg/5ml Suspension
Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This
More informationPatient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 + RITUXIMAB
Patient identifier/label: Page 1 of 6 FORM CHOP 21 + RITUXIMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital
More informationPatient Group Direction for Aspirin 300mg Version: 02 Start Date: 1 st October 2017 Expiry Date: 30 th September 2019
THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG, Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire
More informationStudent Nurses. Medical Day Stay Unit. Student Name:
Student Nurses Medical Day Stay Unit Student Name: Student Contact Details for MDS unit The staff on the unit/department care about your well-being as well as your education. They will notice and be concerned
More informationPRESCRIBING SUPPORT TECHNICIAN:
PRESCRIBING SUPPORT TEAM AUDIT: CARDURA XL (Updated Sept 09) DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Cardura XL is a once daily, extended release preparation of doxazosin
More informationTHE TREATMENT OF BACTERIAL VAGINOSIS (BV) OR TRICHOMONAS VAGINALIS
PGD3717 PATIENT GROUP DIRECTION FOR THESUPPLY OF METRONIDAZOLE 400mg TABLETSFOR THE TREATMENT OF BACTERIAL VAGINOSIS (BV) OR TRICHOMONAS VAGINALIS (TV) by registered nurses and midwives in Integrated Sexual
More informationInflammatory bowel disease service. Information for patients
Inflammatory bowel disease service Information for patients We ve written this leaflet to explain about our inflammatory bowel disease (IBD) service. If you have ulcerative colitis, Crohn s disease or
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Vinorelbine (oral) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
More informationOral Ibrutinib (single agent)
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM IBRUTINIB Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other
More informationSupply of Fusidic Acid Cream 2% by Community Pharmacists for the treatment of impetigo in patients 2 years of age and over.
Supply of Fusidic Acid Cream 2% by Community Pharmacists for the treatment of impetigo in patients 2 years of age and over. November 2017 Review Nov 2019 Signatures of those developing the Patient Group
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Lenvatinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
More informationMETHOTREXATE TOXICITY
METHOTREXATE TOXICITY AN INQUIRY INTO THE DEATH OF A CAMBRIDGESHIRE PATIENT IN APRIL 2000 CAMBRIDGESHIRE HEALTH AUTHORITY JULY 2000 CONTENTS PAGE 1 Introduction 2 2 Background 2 3 Context 2 4 Purpose of
More informationPATIENT GROUP DIRECTION
PATIENT GROUP DIRECTION FOR THE SUPPLY OF FUSIDIC ACID CREAM 2% FOR THE TREATMENT OF IMPETIGO BY COMMUNITY PHARMACISTS UNDER THE PHARMACY FIRST SERVICE IN NHS HIGHLAND THE COMMUNITY PHARMACIST SEEKING
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Lomustine PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
More informationGG&C PGD ref no: 2017/1426 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2017/1426 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Immunisation
More informationSupporting Self Care Choose Pharmacy Common Ailments Service GP Practice Guide
Supporting Self Care Choose Pharmacy Common Ailments Service GP Practice Guide Contents Section 1: Introduction Section 2: Service Information Section 3: Conditions to be Treated Section 4: Referrals &
More informationGG&C PGD ref no: 2011/841 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2011/841 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria:
More informationNational clinical audit of inpatient care for adults with ulcerative colitis
National clinical audit of inpatient care for adults with ulcerative colitis UK inflammatory bowel disease (IBD) audit Executive summary report June 2014 Prepared by the Clinical Effectiveness and Evaluation
More informationProtocol Applies To: UW Health Clinics: all adult outpatients with an active order for warfarin
Protocol Number: 7 Protocol Title: Ambulatory Initiation and Management of Warfarin for Adults Protocol Applies To: UW Health Clinics: all adult outpatients with an active order for warfarin Target Patient
More informationPATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG CAPSULES / TABLETS FOR THE FIRST- LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION
This Patient Group Direction () must only be used by registered pharmacists who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version
More informationPROTOCOL FOR THE ADMINISTRATION OF SENNA. Formulary and Prescribing Guidelines
PROTOCOL FOR THE ADMINISTRATION OF SENNA Formulary and Prescribing Guidelines Introduction This protocol allows for the administration of Senna by a registered nurse without a prescription from a doctor
More informationPATIENT AGREEMENT TO SYSTEMIC THERAPY: GENERIC CONSENT FORM. Patient s first names. Date of birth. Job title
Patient identifier/label: Page 1 of 5 GENERIC CONSENT FORM Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other identifier) Male Female Special requirements
More informationSafer use of anticoagulants: the NPSA patient safety alert Steve Chaplin MSc, MRPharmS
Safer use of anticoagulants: the NPSA patient safety alert Steve Chaplin MSc, MRPharmS Steve Chaplin describes the NPSA s anticoagulant patient safety alert and the measures it recommends for making the
More informationOxfordshire Anticoagulation Service. Important information about anticoagulation with vitamin K antagonists Information for patients
Oxfordshire Anticoagulation Service Important information about anticoagulation with vitamin K antagonists Information for patients Page 2 Your information Name:... Address:......... or patient stickie
More informationStandard Operating Procedure for When required (PRN) medicines in care homes
Standard Operating Procedure for When required (PRN) medicines in care homes Introduction All health and social care organisations are responsible for ensuring the safe management of all medicines. This
More informationSupply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 1
Supply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 Date protocol prepared: December 2015 Date protocol due for review: December 2017 This patient group direction
More informationPatient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CYTARABINE CONTINUOUS INFUSION
Patient identifier/label: Page 1 of 6 CYTARABINE Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital
More informationSUPPLY BY PHARMACISTS OF A NON-PRESCRIPTION MEDICINAL PRODUCT CONTAINING LEVONORGESTREL (NORLEVO 1.5MG TABLETS) AS EMERGENCY HORMONAL CONTRACEPTION
SUPPLY BY PHARMACISTS OF A NON-PRESCRIPTION MEDICINAL PRODUCT CONTAINING LEVONORGESTREL (NORLEVO 1.5MG TABLETS) AS EMERGENCY HORMONAL CONTRACEPTION GUIDANCE FOR PHARMACISTS ON SAFE SUPPLY TO PATIENTS (This
More informationBest Practice Guidance for Supplementary Prescribing by Nurses Within the HPSS in Northern Ireland. patient CMP
Best Practice Guidance for Supplementary Prescribing by Nurses Within the HPSS in Northern Ireland patient CMP nurse doctor For further information relating to Nurse Prescribing please contact the Nurse
More informationCamden Clinical Commissioning Group Reporting Mechanism/Frequency Remotely/Quarterly
Universal Offer Service Anticoagulation - Warfarin Clinical Lead Dr Kevan Ritchie Commissioner Camden Clinical Commissioning Group Reporting Mechanism/Frequency Remotely/Quarterly Payment Frequency Quarterly
More informationBEST PRACTICE GUIDANCE-SUPPLEMENTARY PRESCRIBING
BEST PRACTICE GUIDANCE-SUPPLEMENTARY PRESCRIBING NON MEDICAL PRESCRIBING ADVISOR IMPLEMENTATION DATE: MAY 2009 REVIEW DATE: MAY 2010 Supplementary Prescribing The working definition of supplementary prescribing
More informationPrimary care attitudes to methotrexate monitoring
Quality in Primary Care 2012;20:443 7 # 2012 Radcliffe Publishing Research paper Primary care attitudes to methotrexate monitoring Rachel Byng-Maddick MBBS BSc MRCP (Rheum) Specialist Registrar in Rheumatology,
More informationNHS Lothian Patient Group Direction Version: 001
PATIENT GROUP DIRECTION FOR THE SUPPLY OF FUSIDIC ACID CREAM 2% TO TREAT MINOR STAPHYLOCOCCAL SKIN INFECTIONS (IMPETIGO) IN PATIENTS AGED OVER 2 YEARS BY PHARMACISTS WORKING WITHIN NHS LOTHIAN COMMUNITY
More informationAnticoagulation: Safe prescribing, dispensing and administration of oral and parenteral anticoagulants
Trust Policy Anticoagulation: Safe prescribing, dispensing and administration of oral and parenteral anticoagulants Purpose Date Version March 2015 2 To manage the inherent risks to patients from the use
More informationCommunity Pharmacy: local healthcare. Gill Hall Service Development Office South Staffs LPC
Community Pharmacy: local healthcare Gill Hall Service Development Office South Staffs LPC Pharmacy and the NHS Pharmacies are independent contractors Each pharmacy enters into a contract with the NHS
More informationSupply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 2
Supply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 2 Date protocol prepared: October 2017 Date protocol due for review: October 2019 Expiry date: October
More informationCLINICAL GUIDELINE FOR IPRATROPIUM BROMIDE NEBULISER INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline
CLINICAL GUIDELINE FOR IPRATROPIUM BROMIDE NEBULISER INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical
More informationPROCEDURE FOR THE ADMINISTRATION OF HOMELY REMEDIES IN COMMUNITY HOSPITALS
PROCEDURE FOR THE ADMINISTRATION OF HOMELY REMEDIES IN COMMUNITY HOSPITALS Document Details Title Procedure for the administration of Homely Remedies in Community Hospitals Trust Ref No 1896-36344 Local
More informationMULTI-AGENCY REFERRAL FORM
MULTI-AGENCY REFERRAL FORM For referral of patients who have difficulty managing their prescribed medication. Complete the form and forward it to the patient s community pharmacist Patient name: Telephone:
More informationDocument ref. no: Trust Policy and Procedure PP(16)238 MANAGEMENT OF ADULT PATIENTS TREATED WITH ORAL ANTICOAGULANTS. Approved
Document ref. no: Trust Policy and Procedure PP(16)238 MANAGEMENT OF ADULT PATIENTS TREATED WITH ORAL ANTICOAGULANTS For use in: For use by: For use for: Document owner: Status: West Suffolk NHS Foundation
More informationSymptomatic Relief Policy Compiled by: Drug Adminstration Steering Group Date: July 2004 Review Date: July 2006
Symptomatic Relief Policy Compiled by: Drug Adminstration Steering Group Date: July 2004 Review Date: July 2006 Drug Administration Steering Group 1 Index Page Introduction 3 Clinical Conditions to which
More informationPATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM WEEKLY RITUXIMAB. Patient s first names. Date of birth
Page 1 of 5 FORM WEEKLY RITUXIMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital NHS number
More informationProvide Safe and Effective Medicines Management in Primary Care
Primary Drivers Secondary Drivers Aim Safe and reliable prescribing, monitoring and administration of high risk medications that require systematic monitoring Implement systems for reliable prescribing
More informationPreventing hospital-acquired blood clots
Preventing hospital-acquired blood clots Haematology Department Patient information leaflet This leaflet explains more about blood clots, which can form after illness and surgery. What are hospital-acquired
More informationDEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR MEDICARE & MEDICAID SERVICES
Use for a resident who has potentially unnecessary medications, is prescribed psychotropic medications or has the potential for an adverse outcome to determine whether facility practices are in place to
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cabozantinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
More informationxrfslt \j,3 0+ {6^1 Otc(L!?i:lr+ NHS FIFE PRIMARY CARE THIS PATIENT GROUP DIRECTION HAS BEEN APPROVED BY:
NHS FIFE PRIMARY CARE Patient Group Direction for Named Nurses in Contraception and Sexual Health Clinics to Supply Clotrim azole lo/o cream TO WOMEN CLIENTS for use in the treatment of vaginal candidiasis
More informationVIEKIRA PAK and VIEKIRA PAK-RBV *
VIEKIRA PAK and VIEKIRA PAK-RBV * *ribavirin ABB0017 Patient Booklet.indd 1 Contents Getting started with VIEKIRA PAK or VIEKIRA PAK-RBV 1 Frequently asked questions about treatment 8 Other frequently
More informationANTICOAGULATION MONITORING SERVICE. Standard Operating Procedure For the provision of a Level 3, 4 and 5 Anticoagulation Service
ANTICOAGULATION MONITORING SERVICE Standard Operating Procedure For the provision of a Level 3, 4 and 5 Anticoagulation Service Version: Date at ET/PEC: September 2008 Date ratified at Board: Name and
More informationBlood / Blood Products Transfusion A Liquid Transplant
Blood / Blood Products Transfusion A Liquid Transplant Caroline Holt Specialist Practitioner of Transfusion caroline.holt@tgh.nhs.uk Tel : 922 5484 Mob: 07759260044 The Transfusion Team Gillian Lewis Blood
More informationOPAT CELLULITIS PATHWAY
OPAT CELLULITIS PATHWAY ANY exclusion criteria for OPAT Sepsis syndrome Active drug/alcohol abuse Active underlying orthopaedic condition Craniofacial cellulitis Failure to improve with > 48hrs IV Rx YES
More informationPharmacy First is primarily a service to support and improve self-care.
Self-Care Service The Pharmacy First service is commissioned by to provide the local population with rapid access to a pharmacist who can give self-care advice on a range of minor ailments. This will release
More informationAdverse Drug Events: A Focus on Anticoagulation Steve Meisel, Pharm.D., CPPS Director of Patient Safety Fairview Health Services, Minneapolis, MN
Adverse Drug Events: A Focus on Anticoagulation Steve Meisel, Pharm.D., CPPS Director of Patient Safety Fairview Health Services, Minneapolis, MN Fairview Health Services 6 hospitals, ranging from rural
More informationPatient Group Direction For the supply of Fusidic Acid 2% Cream
Patient Group Direction For the supply of Fusidic Acid 2% Cream This Patient Group Direction (PGD) is a specific written instruction for the supply of Fusidic Acid 2% Cream to groups of patients who may
More informationPractice Tools for Safe Drug Therapy
Practice Tools for Safe Drug Therapy Practice Tools for Safe Drug Therapy Pharmacists and pharmacy technicians make sure the right person gets the right dose of the right drug at the right time and takes
More informationLinda Cutter / Dr Charles Heatley. GP Practices and Community Pharmacies
Schedule 2 Part A Service Specification Service Specification No. 04 Service Anti-coagulation Monitoring Levels 3, 4 & 5 Commissioner Lead Provider Lead Linda Cutter / Dr Charles Heatley GP Practices and
More informationThe use of Homely Remedies in Care Homes
Good Practice Guidance: The use of Homely Remedies in Care Homes The aim of this guidance is to: Support and advise care homes in the development of a homely remedy policy that adheres to the NICE good
More informationAlert. Patient safety alert. Actions that can make anticoagulant therapy safer. 28 March Action for the NHS and the independent sector
Patient safety alert 18 Alert 28 March 2007 Immediate action Action Update Information request Ref: NPSA/2007/18 Actions that can make anticoagulant therapy safer Anticoagulants are one of the classes
More information